期刊
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
卷 108, 期 -, 页码 73-85出版社
ELSEVIER SCIENCE INC
DOI: 10.1016/j.critrevonc.2016.10.010
关键词
PARP inhibitor; Drug combinations; BRCA1; BRCA2
资金
- Breast Cancer Now
- Cancer Research UK
- Wellcome Trust
- Breast Cancer Research Foundation
- Komen Foundation
- UCSF
- Cancer Research UK [14276] Funding Source: researchfish
In 2014, olaparib (Lynparza) became the first PARP (Poly(ADP-ribose) polymerase) inhibitor to be approved for the treatment of cancer. When used as single agents, PARP inhibitors can selectively target tumour cells with BRCA1 or BRCA2 tumour suppressor gene mutations through synthetic lethality. However, PARP inhibition also shows considerable promise when used together with other therapeutic agents. Here, we summarise both the pre-clinical and clinical evidence for the utility of such combinations and discuss the future prospects and challenges for PARP inhibitor combinatorial therapies. (C) 2016 Elsevier Ireland Ltd. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据